Isogenica announces latest board level appointment. Göran Forsberg, Chief Business Officer at Active Biotech joins Isogenica as non-executive Director.

12:59 EDT 2 Nov 2011 | BioPortfolio

Isogenica today announced the appointment of Göran Forsberg to the Board of Directors.

Currently Chief Business Officer (CBO) at Active Biotech in Lund, Sweden, Göran brings extensive industry experience to Isogenica. He holds a Ph.D. in Biochemistry from the Royal Institute of Technology, Stockholm, Sweden and has authored approximately 40 scientific articles primarily within biochemistry, molecular biology, immunology and cancer research. Göran has worked in the pharmaceutical industry for almost 25 years as a scientist, project leader or department head within KabiGen, Pharmacia and the University of Adelaide. Since 2008, he has been responsible for business development at Active Biotech, a company developing new products for the treatment of autoimmune diseases and cancer with three products in pivotal clinical studies.

Dr Kevin Matthews, CEO, Isogenica commented of the appointment:  “We are delighted to welcome Göran to the board.  His significant experience within the industry, both at a scientific and commercial level, will be invaluable to Isogenica as we continue to expand our capabilities - working in partnership with our clients to discover highly active lead candidates for drug development - with the ultimate goal of identifying channels to market for these new and potent therapeutic peptides.”

Isogenica has enjoyed significant expansion of its capabilities during 2011.  March saw the establishment of a dedicated business development and customer support team in North America, providing direct support to Isogenica’s existing and prospective customers in the United States and Canada. In July the company announced the opening of a new automation facility at their current UK base, Chesterford Research Park. Following a substantial refit of additionally acquired space, the new facility is now home to the high throughput CIS display platform used in the discovery of biological therapeutics, diagnostics and reagents using Tecan liquid handling robots and screening equipment. This development brings additional capacity to the company for the selection of next generation molecules for biopharmaceutical projects with a capacity of up to two hundred selections per week.

About Isogenica: Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display.  Founded in 2000 Isogenica has developed a unique capability in the field of protein engineering.  Isogenica's CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.

Sarah Brereton, Limewash Media & Design Ltd NEXT ARTICLE

More From BioPortfolio on "Isogenica announces latest board level appointment. Göran Forsberg, Chief Business Officer at Active Biotech joins Isogenica as non-executive Director."

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...